Hare Wynn attorneys have a long history of representing consumers suffering serious injuries or death resulting from dangerous and defective drugs and devices placed on the market by pharmaceutical and medical device companies.
Beginning in the 1970s with Thalidomide and the Swine Flu Vaccine Litigation, continuing with breast implant litigation, Vioxx, Zofran, metal-on-metal hips and IVC filters today, Hare Wynn continues to represent individuals in drug and device cases.
Hare Wynn is one of the premiere pharmaceutical and medical device firms in the country—our results in obtaining eight figure recoveries for our client speak for themselves. Four strategically located offices and national resources allow our firm to obtain recoveries among the highest in the nation.
We regularly try our cases and defendants know it. Hare Wynn partners are among the most experienced trial lawyers in the country. Some of our successes and recognition include:
- In recent trials against Bayer, we were successful in obtaining two verdicts totaling over $50,000,000 for our clients.
- Teaming with the Commonwealth of Kentucky’s Attorney General’s Office, we obtained a $25,000,000 result related to Merck’s marketing of its blockbuster pain drug, Vioxx.
- The National Law Journal recently recognized Hare Wynn for obtaining one of the top 100 verdicts in America in three of the last four years.
Hare Wynn currently is investigating claims based on a number of pharmaceuticals and medical devices. We regularly team with referring attorneys to enhance the value of the cases. The following are among the claims we are investigating currently. Contact information for Hare Wynn attorneys working on these cases is included.
Metal-on-Metal Hip Litigation
Scott Powell was recently appointed to the Plaintiff’s Steering Committee in the Biomet Hip M2A/M2A Magnum litigation. In addition, Don McKenna has been appointed to a leadership role in claims against Stryker related to its Rejuvenate and ABG II metal-on-metal hips. Hare Wynn is currently handling claims related to the following hips: DePuy ASR, DePuy Pinnacle, Magnum, Smith & Nephew R3 Acetabular Hip System, Wright CONSERVE and the Zimmer Duron Cup. Our firm has developed procedures to efficiently determine the manufacturer of your client’s hip, to complete blood tests for the presence of metal ions related to the faulty hips, and to preserve your client’s explanted hip after revision surgery. Contact Don McKenna to discuss these cases further.
Incretins Mimetics Drugs Pancreatic Cancer Litigation
Hare Wynn is also investigating claims for individuals that have developed pancreatic cancer while taking the newest generation of diabetes drugs—Januvia (Merck), Janumet (Merck), Victoza (Novo Nordisk), and Byetta (Eli Lilly). In addition, we are considering claims for thyroid cancer developed while taking Byetta. These drugs are among the most widely prescribed drugs in the nation and are heavily marketed by pharmaceutical companies. Recent studies have suggested a link between the use of these types of drugs and an increased risk for pancreatic cancer. Mike Ermert and Brian Vines are leading our firm’s effort in these cases.
Pradaxa Hemorrhaging Litigation
Finally, Hare Wynn is investigating claims on behalf of individuals who have suffered life-threatening brain and gastrointestinal bleeds related to their use of Pradaxa. Pradaxa is sometimes prescribed to patients after hip or knee replacement surgery to prevent blood clots and has been linked to excessive and serious bleeding in the brain and gastrointestinal system. In addition, another safety concern is that if a patient suddenly stops taking Pradaxa it can cause heart attacks or strokes. Because there is no reversing agent for Pradaxa, this combination can create life threatening situations for patients. Scott Powell is heading up this litigation for Hare Wynn.
Attorney General Vioxx Litigation
Hare Wynn continues to represent several states, including Montana and Alaska, against Merck, related to that pharmaceutical company’s promotion of Vioxx. Recently, Hare Wynn, served as outside counsel for The Commonwealth of Kentucky in a lawsuit filed by the Attorney General of that state against Merck pursuant to the Kentucky Consumer Protection Act. The case was settled for $25 million.
Xarelto (rivaroxaban) is a new generation blood thinner which was approved by the FDA on July 1, 2011. Xarelto has been approved to prevent deep vein thrombosis after knee replacement surgery and hip replacement surgery and to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation. The most dangerous side effect for people taking Xarelto is uncontrollable bleeding. The manufacturers of Xarelto claim that blood tests are not needed for patients taking this drug. Because Xarelto’s ability to thin blood varies widely between patients, the lack of a simple blood-test prevents patients and physicians from knowing whether Xarelto causes a patient’s blood to become too thin leading to uncontrolled bleeding events.
Hare Wynn is currently investigating the following injuries related to the use of Xarelto:
- Irreversible bleeding
- Gatrointestinal bleeding
- Intracranial bleeding
If you or a loved one has taken Xarelto and have developed any of these injuries, please contact us. We are currently evaluating claims.